A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV)
Journal of Infection and Public Health · 2024-05 · 17 (5) · 897-905
DOI: 10.1016/j.jiph.2024.03.030 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Infection and Public Health, 2024-05. Verfasst von Taweegrit Siripongboonsitti und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand; Princess Srisavangavadhana…. Hauptthemen laut MEDLINE: COVID-19, Amides, Pyrazines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health Foundation, Chulabhorn Royal Academy.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand; Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand. Ele…
- Division of Infectious Diseases, Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand; Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand.
- Division of Dengue Hemorrhagic Fever Research, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Siriraj Center of Research Excellence in Dengue and Eme…
- Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Förderung
- National Health Foundation
- Chulabhorn Royal Academy
Zitieren
APA
Siripongboonsitti, T., Tawinprai, K., Avirutnan, P., Jitobaom, K., & Auewarakul, P. (2024). A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV). Journal of Infection and Public Health, 17(5), 897-905. https://doi.org/10.1016/j.jiph.2024.03.030
Vancouver
Siripongboonsitti T, Tawinprai K, Avirutnan P, Jitobaom K, Auewarakul P. A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV). Journal of Infection and Public Health. 2024;17(5):897-905. doi:10.1016/j.jiph.2024.03.030
BibTeX
@article{Siripongboonsitti2024,
author = {Siripongboonsitti, Taweegrit and Tawinprai, Kriangkrai and Avirutnan, Panisadee and Jitobaom, Kunlakanya and Auewarakul, Prasert},
title = {A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV)},
journal = {Journal of Infection and Public Health},
year = {2024},
volume = {17},
number = {5},
pages = {897--905},
doi = {10.1016/j.jiph.2024.03.030}
}
EUVIMED